If you've been tracking biotech news or seen headlines about a stock plummeting, you might be wondering what's going on with Wave Life Sciences. This company just saw its stock crash by over 50% in a single day, but the reason why reveals a surprising truth about the high-stakes world of drug development.
Wave Life Sciences (WVE) stock plunged over 50% in one day, wiping out more than $200 million in market value.
This dramatic drop on June 10, 2024, came after the company released disappointing early-stage clinical trial results for its new obesity drug candidate, WVE-N531, causing a significant investor sell-off.